HSBC DIS.CERT. 02/25 FRE/ DE000HS7AJB4 /
19/11/2024 11:37:19 | Var.0.000 | Denaro12:22:48 | Lettera12:22:48 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
29.300EUR | 0.00% | 29.290 Quantità in denaro: 5,000 |
29.310 Quantità in lettera: 5,000 |
FRESENIUS SE+CO.KGAA... | - EUR | 28/02/2025 | Call |
GlobeNewswire
23/04
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
23/02
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
04/09/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
31/08/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
24/08/2023
CIO Leadership: The Steps Needed to Build a High-Performance Culture Will Power the Discussion at th...
GlobeNewswire
25/02/2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
05/01/2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
31/12/2021
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
09/12/2021
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
22/11/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
22/11/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology